Source comparison
Peptide Comparison: Discontinuation Difficulty and Recovery Timelines
Different peptides carry different cessation profiles. Stopping tesamorelin + ipamorelin blend is physiologically simpler than stopping other growth hormone pathways because secretagogues don't suppress the hypothalamic-pituitary axis the way exogenous GH does
This comparison does not assign a generated winner or score.
- Different peptides carry different cessation profiles. Stopping tesamorelin + ipamorelin blend is physiologically simpler than stopping other growth hormone pathways because secretagogues don't suppress the hypothalamic-pituitary axis the way exogenous GH does. Here's how the discontinuation difficulty compares across common research peptides:
- Tesamorelin + Ipamorelin
- GHRH analog + ghrelin mimetic (secretagogue pathway)
- Low to Moderate
- 4–8 weeks for IGF-1 normalization
- Fatigue, sleep disruption, mild joint stiffness. Resolves within 6–8 weeks
- Easiest GH-modulating peptide to discontinue. No true suppression, only adaptation lag. Taper recommended but not mandatory.
- Exogenous Growth Hormone (Somatropin)
- Direct GH replacement
- High
- 8–16 weeks; may require secretagogue bridge therapy
- Severe fatigue, mood disturbance, metabolic slowdown. Symptoms persist 10–14 weeks
- Causes true pituitary suppression. Requires structured taper and post-cycle GH secretagogue support to restore endogenous pulsatility.
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic (continuous elevation)
- Moderate
- 6–10 weeks
- Appetite normalization takes 2–4 weeks, water weight drops rapidly, sleep quality declines temporarily
- Continuous receptor stimulation creates stronger adaptation than pulsatile peptides. Taper essential to avoid rebound hunger and cortisol spike.
- CJC-1295 (with DAC)
- Long-acting GHRH analog
- Moderate to High
- 10–14 weeks due to extended half-life
- Prolonged IGF-1 decline, fatigue lasting 8–12 weeks
- DAC (Drug Affinity Complex) extends half-life to 6–8 days. Even after stopping, exogenous signaling persists for weeks. Taper provides minimal benefit.
- The bottom line: tesamorelin + ipamorelin blend sits at the safer end of the discontinuation spectrum because both peptides have short half-lives (tesamorelin <1 hour, ipamorelin 2 hours) and work by stimulating your own GH release rather than replacing it. You're not shutting down endogenous production. You're just removing the amplification signal. Recovery is a ramp-up period, not a restoration-from-suppression crisis.